BSN CAPITAL PARTNERS Ltd Purchases New Shares in Eli Lilly and Company (NYSE:LLY)

BSN CAPITAL PARTNERS Ltd acquired a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 18,000 shares of the company’s stock, valued at approximately $16,785,000. Eli Lilly and Company comprises about 3.2% of BSN CAPITAL PARTNERS Ltd’s portfolio, making the stock its 10th biggest holding.

Other large investors have also recently added to or reduced their stakes in the company. Lynx Investment Advisory bought a new position in shares of Eli Lilly and Company in the 2nd quarter worth about $32,000. LGT Financial Advisors LLC acquired a new position in Eli Lilly and Company during the 2nd quarter valued at about $36,000. Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the 1st quarter valued at about $40,000. Morton Brown Family Wealth LLC grew its stake in shares of Eli Lilly and Company by 45.5% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after purchasing an additional 15 shares during the last quarter. Finally, Richardson Financial Services Inc. acquired a new position in shares of Eli Lilly and Company in the 4th quarter worth approximately $43,000. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Up 0.7 %

Shares of LLY stock opened at $919.91 on Thursday. The firm has a fifty day moving average of $906.72 and a 200-day moving average of $850.80. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53. The stock has a market cap of $874.29 billion, a price-to-earnings ratio of 135.48, a P/E/G ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, topping the consensus estimate of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. On average, equities research analysts forecast that Eli Lilly and Company will post 16.49 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have commented on LLY shares. Guggenheim raised their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a report on Friday, August 16th. BMO Capital Markets lifted their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Jefferies Financial Group lifted their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a research report on Monday, June 24th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus price target of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.